Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.

Paolo Tarantino, Sarah Sammons, Julia Foldi et al.|Journal of Clinical Oncology|2024

Cited by 13